NCT03061513View on ClinicalTrials.gov

Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Parkinson Disease
Interventions
DRUG

Ubiquinol

Ubiquinol caplets 600mg/day

DIETARY_SUPPLEMENT

Placebo

placebo

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT03061513 - Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers | Biotech Hunter | Biotech Hunter